Vertex Pharmaceuticals Revenue 2006-2021 | VRTX

Vertex Pharmaceuticals annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Vertex Pharmaceuticals revenue for the quarter ending June 30, 2021 was $1.793B, a 17.64% increase year-over-year.
  • Vertex Pharmaceuticals revenue for the twelve months ending June 30, 2021 was $6.684B, a 23.71% increase year-over-year.
  • Vertex Pharmaceuticals annual revenue for 2020 was $6.206B, a 49.07% increase from 2019.
  • Vertex Pharmaceuticals annual revenue for 2019 was $4.163B, a 36.59% increase from 2018.
  • Vertex Pharmaceuticals annual revenue for 2018 was $3.048B, a 22.46% increase from 2017.
Vertex Pharmaceuticals Annual Revenue
(Millions of US $)
2020 $6,206
2019 $4,163
2018 $3,048
2017 $2,489
2016 $1,702
2015 $1,032
2014 $580
2013 $1,212
2012 $1,527
2011 $1,411
2010 $143
2009 $102
2008 $176
2007 $199
2006 $216
2005 $161
Vertex Pharmaceuticals Quarterly Revenue
(Millions of US $)
2021-06-30 $1,793
2021-03-31 $1,724
2020-12-31 $1,628
2020-09-30 $1,538
2020-06-30 $1,524
2020-03-31 $1,515
2019-12-31 $1,413
2019-09-30 $950
2019-06-30 $941
2019-03-31 $858
2018-12-31 $870
2018-09-30 $785
2018-06-30 $752
2018-03-31 $641
2017-12-31 $652
2017-09-30 $578
2017-06-30 $544
2017-03-31 $715
2016-12-31 $459
2016-09-30 $414
2016-06-30 $432
2016-03-31 $398
2015-12-31 $418
2015-09-30 $310
2015-06-30 $166
2015-03-31 $139
2014-12-31 $145
2014-09-30 $179
2014-06-30 $138
2014-03-31 $118
2013-12-31 $351
2013-09-30 $222
2013-06-30 $311
2013-03-31 $328
2012-12-31 $334
2012-09-30 $336
2012-06-30 $418
2012-03-31 $439
2011-12-31 $563
2011-09-30 $659
2011-06-30 $114
2011-03-31 $74
2010-12-31 $66
2010-09-30 $24
2010-06-30 $32
2010-03-31 $22
2009-12-31 $34
2009-09-30 $25
2009-06-30 $19
2009-03-31 $24
2008-12-31 $33
2008-09-30 $32
2008-06-30 $69
2008-03-31 $42
2007-12-31 $51
2007-09-30 $41
2007-06-30 $38
2007-03-31 $69
2006-12-31 $94
2006-09-30 $53
2006-06-30 $30
2006-03-31 $39
2005-12-31 $64
2005-09-30 $36
2005-06-30 $32
2005-03-31 $29
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $47.156B $6.206B
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00